Advertisement

High-Throughput Screening for Identification of Novel Innate Immune Activators

  • Bryan J. Gall
  • Victor R. DeFilippisEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1656)

Abstract

Modern drug discovery has embraced in vitro platforms that enable investigation of large numbers of compounds within tractable timeframes and for feasible costs. These endeavors have been greatly aided in recent years by advances in molecular and cell-based methods such as gene delivery and editing technology, advanced imaging, robotics, and quantitative analysis. As such, the examination of phenotypic impacts of novel molecules may only be limited by the size of the compound collection. Innate immune signaling processes in mammalian cells are especially amenable to high-throughput screening platforms since the cellular responses elicited by their activation often result in high level transcription that can be harnessed in the form of bioluminescent or fluorescent signal. In addition, targeted activation of innate immune pathways represents a valuable therapeutic strategy applicable to multiple chronic and acute human diseases. Herein, we describe the optimization and utilization of a high-throughput screening method using human reporter cells reactive to stimulation of the type I interferon response. Importantly, the principles and methods described can be applied to adherent reporter cells of diverse derivation and innate signaling pathway readouts.

Key words

STING Drug discovery High-throughput screening Innate immunity Signaling 

References

  1. 1.
    Qian C, Liu J, Cao X (2014) Innate signaling in the inflammatory immune disorders. Cytokine Growth Factor Rev 25:731–738CrossRefGoogle Scholar
  2. 2.
    McNab F, Mayer-Barber K, Sher A, Wack A, O’Garra A (2015) Type I interferons in infectious disease. Nat Publ Group 15:87–103Google Scholar
  3. 3.
    Schenten D, Medzhitov R (2011) The control of adaptive immune responses by the innate immune system. Adv Immunol 109:87–124CrossRefGoogle Scholar
  4. 4.
    Ulevitch RJ (2004) Therapeutics targeting the innate immune system. Nat Rev Immunol 4:512–520CrossRefGoogle Scholar
  5. 5.
    Brubaker SW, Bonham KS, Zanoni I, Kagan JC (2015) Innate immune pattern recognition: a cell biological perspective. Annu Rev Immunol 33:257–290CrossRefGoogle Scholar
  6. 6.
    Kaskova ZM, Tsarkova AS, Yampolsky IV (2016) 1001 lights: luciferins, luciferases, their mechanisms of action and applications in chemical analysis, biology and medicine. Chem Soc Rev 45:6048–6077CrossRefGoogle Scholar
  7. 7.
    Chudakov DM, Matz MV, Lukyanov S, Lukyanov KA (2010) Fluorescent proteins and their applications in imaging living cells and tissues. Physiol Rev 90:1103–1163CrossRefGoogle Scholar
  8. 8.
    Roda A, Mirasoli M, Michelini E, Di Fusco M, Zangheri M, Cevenini L, Roda B, Simoni P (2016) Progress in chemical luminescence-based biosensors: a critical review. Biosens Bioelectron 76:164–179CrossRefGoogle Scholar
  9. 9.
    Defilippis VR, Sali T, Alvarado D, White L, Bresnahan W, Früh KJ (2010) Activation of the interferon response by human cytomegalovirus occurs via cytoplasmic double-stranded DNA but not glycoprotein B. J Virol 84:8913–8925CrossRefGoogle Scholar
  10. 10.
    Zhang J, Chung T, Oldenburg K (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67–73CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2017

Authors and Affiliations

  1. 1.Vaccine and Gene Therapy InstituteOregon Health and Science UniversityBeavertonUSA

Personalised recommendations